Profile cover photo
Profile photo
Actinogen Medical Limited
3 followers
3 followers
About
Actinogen Medical Limited's posts

Post has attachment
Actinogen Medical announces landmark research on excess cortisol and Alzheimer's disease.

Post has attachment
A successful time at AAIC 2016 for Actinogen Medical and AIBL group with the display of their respective studies in poster sessions and feature presentations throughout the conference.
Photo
Photo
2016-07-27
2 Photos - View album

Post has attachment
Actinogen Medical is pleased to announce a grant for the most comprehensive US Patent to expand the current protection of Xanamem™ to 2031 for use in the treatment of Alzheimer's disease.

Post has attachment
Pleased to announce the showcase of both Xanamem and AIBL data in support of the cortisol hypothesis in Alzheimer's disease at this year's AAIC in Toronto, Canada. Check it out by following the link below.

Post has attachment
Actinogen Medical is excited to present at this week's Wholesale Investor Small Cap Showcase. Register today to come view the presentation by CEO, Dr. Bill Ketelbey, with a chance to meet him following the company presentations.

Post has attachment

Post has attachment
Exciting news to share as this fantastic year comes to an end - Be sure to see our December Newsletter for updates on Xanamem and our team!

Post has attachment
Martin Rogers with speaker Bryce Vissel, from The Garvan Institute, and guests, at tonight's "Understanding Alzheimer's" event — at Sofitel Sydney Wentworth.
Photo

Post has attachment
This evening at the "Understanding Alzheimer's" event hosted by Actinogen Medical at the Sofitel Sydney Wentworth, our speakers all shared their passions for discovery research, treatment, and patient advocacy. Specifically, Dr. Katarina Kelin from Eli Lilly stated that "we are changing the trajectory and slowing down the disease," in reference to Alzheimer's disease. Check out our live feed on Twitter (@ActinogenMed) and live stream on Periscope (@martinfrogers). News and updates are also being covered by our partners Buchan Consulting (@BuchanIR).
Photo

Post has attachment
Actinogen Medical is excited to share the following news: "Positive trial results for Alzheimer's drug Xanamem™". See below:
Wait while more posts are being loaded